Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Study Purpose
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab and sorafenib may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving bevacizumab together with sorafenib may kill more tumor cells. PURPOSE: This phase II trial is studying the side effects and how well giving bevacizumab together with sorafenib works in treating patients with recurrent glioblastoma multiforme.
Recruitment Criteria
|
Accepts Healthy Volunteers
Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms |
No |
|
Study Type
An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes. Searching Both is inclusive of interventional and observational studies. |
Interventional |
| Eligible Ages | 18 Years and Over |
| Gender | All |
DISEASE CHARACTERISTICS:
- - Histologically confirmed glioblastoma multiforme as determined by pre-registration central pathology review.
- - Gliosarcoma allowed.
- - Must have evidence of tumor progression by MRI or CT scan following radiotherapy or the most recent anti-tumor therapy.
- - No more than 1 chemotherapy regimen for progressive or recurrent disease.
- - Bidimensionally measurable or evaluable disease by MRI or CT scan.
- - No evidence of CNS hemorrhage on baseline CT or MRI.
- - Patients with T1 hyperintensity confined to the surgical cavity which is felt likely due to post surgical blood contaminating the intracavity cerebrospinal fluid or irrigation that have not yet absorbed and which is not felt to clinically or radiographically represent new spontaneous hemorrhage are eligible.
- - Patients with old blood products or hemosiderin without a history of spontaneous bleeding are eligible.
- - ECOG performance status 0-2.
- - ANC ≥ 1,500/mm³ - Platelet count ≥ 100,000/mm³ - Hemoglobin > 9.0 g/dL.
- - Total bilirubin ≤ 1.5 times upper limit of normal.
- - AST ≤ 3 times upper limit of normal.
- - Creatinine ≤ upper limit of normal.
- - Urine protein:creatinine ratio < 1 OR urine protein < 1,000 mg by 24-hour urine collection.
- - Not pregnant or nursing.
- - Negative pregnancy test.
- - Fertile patients must use effective contraception during and for six months after completion of study treatment.
- - Able to complete questionnaire(s) alone or with assistance.
- - Willing to return to NCCTG enrolling institution for follow-up.
- - Willing to provide mandatory blood samples for research purposes.
- - Not immunocompromised (other than that related to the use of corticosteroids) - No known HIV positivity.
- - No concurrent uncontrolled illness including, but not limited to, the following: - Ongoing or active infection.
- - Symptomatic congestive heart failure.
- - Unstable angina pectoris.
- - Cardiac arrhythmia.
- - Psychiatric illness/social situations that would limit compliance with study requirements.
- - No inadequately controlled hypertension (i.e., systolic blood pressure [BP] > 150 mm Hg or diastolic BP > 100 mm Hg while on antihypertensive medications) - Patients with well-controlled hypertension are eligible.
- - No myocardial infarction or unstable angina within the past 6 months.
- - No congestive heart failure requiring the use of ongoing maintenance therapy for life-threatening ventricular arrhythmias.
- - No New York Heart Association class II-IV congestive heart failure.
- - No significant vascular disease (e.g., aortic aneurysm or aortic dissection) - No peripheral arterial thrombosis within the past 6 months.
- - No stroke or transient ischemic attack within the past 6 months.
- - No history of hypertensive crisis or hypertensive encephalopathy.
- - No evidence of bleeding diathesis (greater than normal risk of bleeding) or coagulopathy (in the absence of therapeutic anticoagulation) - No active or recent history of hemoptysis (i.e., ≥ ½ teaspoon of bright red blood per episode) within the past 30 days.
- - No serious, nonhealing wounds, ulcers, or bone fractures.
- - No condition that impairs the ability to swallow pills (e.g., gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation) - No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months.
- - No significant traumatic injury within the past 28 days.
- - No known hypersensitivity to any of the components of sorafenib or bevacizumab.
- - No other active malignancy within the past 3 years, except nonmelanoma skin cancer or carcinoma in situ of the cervix.
- - Patients with a history of prior malignancy must not be receiving specific treatment (other than hormonal therapy) for that malignancy.
- - No co-morbid systemic illness or other concurrent severe disease that, in the judgment of the investigator, would make the patient inappropriate for entry into this study or significantly interfere with the proper assessment of safety and toxicity of the prescribed study regimen.
- - See Disease Characteristics.
- - At least 12 weeks since prior radiotherapy.
- - More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) - More than 2 weeks since prior small molecule cell cycle inhibitors.
- - At least 1 week since prior fixed-dose corticosteroids (or no corticosteroids) - No prior intratumoral chemotherapy, stereotactic radiosurgery or interstitial brachytherapy unless there is a separate lesion on MRI that is not part of the prior treatment field OR there is proof of recurrent disease based on biopsy, MRI spectroscopy, or PET scan.
- - No prior antiangiogenic therapy.
- - No prior surgical procedures affecting absorption.
- - More than 7 days since prior core biopsy or other minor surgical procedures.
- - Placement of a vascular access device is allowed.
- - More than 28 days since prior major surgical procedure or open biopsy.
- - No concurrent major surgical procedure.
- - No other concurrent investigational agents.
- - No concurrent enzyme-inducing antiepileptic drugs (e.g., phenytoin, fosphenytoin, carbamazepine, phenobarbital, or primidone) - No other concurrent potent CYP3A4 inducers (e.g., rifampin or St. John's wort) - No concurrent therapeutic anticoagulation with warfarin.
- - Prophylactic anticoagulation (i.e., low-dose warfarin) for venous or arterial access devices allowed provided the INR < 1.5.
Trial Details
|
Trial ID:
This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries. |
NCT00621686 |
|
Phase
Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans. Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data. Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use. |
Phase 2 |
|
Lead Sponsor
The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data. |
Alliance for Clinical Trials in Oncology |
|
Principal Investigator
The person who is responsible for the scientific and technical direction of the entire clinical study. |
Evanthia Galanis, MD |
| Principal Investigator Affiliation | Mayo Clinic |
|
Agency Class
Category of organization(s) involved as sponsor (and collaborator) supporting the trial. |
Other, NIH |
| Overall Status | Completed |
| Countries | United States |
|
Conditions
The disease, disorder, syndrome, illness, or injury that is being studied. |
Brain and Central Nervous System Tumors |
OBJECTIVES: Primary.
- - Identify the clinical efficacy of bevacizumab and sorafenib, as measured by 6-month progression-free survival, in patients with recurrent glioblastoma multiforme.
- - Assess time to progression of this patient population.
- - Assess overall survival of this patient population.
Arms
Experimental: Sorafenib + Bevacizumab/Group A
Patients receive oral sorafenib 400 mg (200 mg twice daily) days 1-5 and 8-12 and 5 mg/kg bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 14 days. Patients undergo blood and plasma sample collection at baseline and then periodically during study treatment for translational research studies. Translational research studies include analysis of circulating endothelial cells and circulating endothelial progenitor cells by flow cytometry and measurement of angiogenic proteins in plasma by ELISA. DNA and buffy coat are extracted and collected from the blood samples for pharmacogenetic studies. Quality of life is assessed at baseline, prior to every other treatment course, and at the end of treatment. After completion of study treatment, patients are followed at 28-42 days, every 3 months for 5 years, and then annually for 10 years.
Experimental: Sorafenib + Bevacizumab /Group B
Patients receive oral sorafenib 200 mg once daily on days 1-14 and 5 mg/kg bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 14 days. Patients undergo blood and plasma sample collection at baseline and then periodically during study treatment for translational research studies. Translational research studies include analysis of circulating endothelial cells and circulating endothelial progenitor cells by flow cytometry and measurement of angiogenic proteins in plasma by ELISA. DNA and buffy coat are extracted and collected from the blood samples for pharmacogenetic studies. Quality of life is assessed at baseline, prior to every other treatment course, and at the end of treatment. After completion of study treatment, patients are followed at 28-42 days, every 3 months for 5 years, and then annually for 10 years.
Interventions
Biological: - bevacizumab
Drug: - sorafenib tosylate
Contact a Trial Team
If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.
Status
Address
Mayo Clinic Scottsdale
Scottsdale, Arizona, 85259-5499
Status
Address
Cancer Care Associates
Fresno, California, 93720
Status
Address
Front Range Cancer Specialists
Fort Collins, Colorado, 80528
Status
Address
Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center
Hartford, Connecticut, 06105
Status
Address
Baptist Cancer Institute - Jacksonville
Jacksonville, Florida, 32207
Status
Address
Mayo Clinic - Jacksonville
Jacksonville, Florida, 32224
Status
Address
Rush-Copley Cancer Care Center
Aurora, Illinois, 60504
Status
Address
Carle Cancer Center at Carle Foundation Hospital
Urbana, Illinois, 61801
Status
Address
CCOP - Carle Cancer Center
Urbana, Illinois, 61801
Status
Address
St. Francis Hospital and Health Centers - Beech Grove Campus
Beech Grove, Indiana, 46107
Status
Address
Reid Hospital & Health Care Services
Richmond, Indiana, 47374
Status
Address
McFarland Clinic, PC
Ames, Iowa, 50010
Status
Address
Cedar Rapids Oncology Associates
Cedar Rapids, Iowa, 52403
Status
Address
Mercy Regional Cancer Center at Mercy Medical Center
Cedar Rapids, Iowa, 52403
Status
Address
Medical Oncology and Hematology Associates - West Des Moines
Clive, Iowa, 50325
Status
Address
Mercy Capitol Hospital
Des Moines, Iowa, 50307
Status
Address
CCOP - Iowa Oncology Research Association
Des Moines, Iowa, 50309
Status
Address
John Stoddard Cancer Center at Iowa Methodist Medical Center
Des Moines, Iowa, 50309
Status
Address
Medical Oncology and Hematology Associates at John Stoddard Cancer Center
Des Moines, Iowa, 50309
Status
Address
Medical Oncology and Hematology Associates at Mercy Cancer Center
Des Moines, Iowa, 50314
Status
Address
Mercy Cancer Center at Mercy Medical Center - Des Moines
Des Moines, Iowa, 50314
Status
Address
John Stoddard Cancer Center at Iowa Lutheran Hospital
Des Moines, Iowa, 50316
Status
Address
McCreery Cancer Center at Ottumwa Regional
Ottumwa, Iowa, 52501
Status
Address
Siouxland Hematology-Oncology Associates, LLP
Sioux City, Iowa, 51101
Status
Address
Mercy Medical Center - Sioux City
Sioux City, Iowa, 51104
Status
Address
St. Luke's Regional Medical Center
Sioux City, Iowa, 51104
Status
Address
Cancer Center of Kansas, PA - Chanute
Chanute, Kansas, 66720
Status
Address
Cancer Center of Kansas, PA - Dodge City
Dodge City, Kansas, 67801
Status
Address
Cancer Center of Kansas, PA - El Dorado
El Dorado, Kansas, 67042
Status
Address
Cancer Center of Kansas - Fort Scott
Fort Scott, Kansas, 66701
Status
Address
Cancer Center of Kansas-Independence
Independence, Kansas, 67301
Status
Address
Cancer Center of Kansas, PA - Kingman
Kingman, Kansas, 67068
Status
Address
Lawrence Memorial Hospital
Lawrence, Kansas, 66044
Status
Address
Southwest Medical Center
Liberal, Kansas, 67901
Status
Address
Cancer Center of Kansas, PA - Newton
Newton, Kansas, 67114
Status
Address
Cancer Center of Kansas, PA - Parsons
Parsons, Kansas, 67357
Status
Address
Cancer Center of Kansas, PA - Pratt
Pratt, Kansas, 67124
Status
Address
Cancer Center of Kansas, PA - Salina
Salina, Kansas, 67401
Status
Address
Cancer Center of Kansas, PA - Wellington
Wellington, Kansas, 67152
Status
Address
Associates in Womens Health, PA - North Review
Wichita, Kansas, 67208
Status
Address
Cancer Center of Kansas, PA - Medical Arts Tower
Wichita, Kansas, 67208
Status
Address
Cancer Center of Kansas, PA - Wichita
Wichita, Kansas, 67214
Status
Address
CCOP - Wichita
Wichita, Kansas, 67214
Status
Address
Via Christi Cancer Center at Via Christi Regional Medical Center
Wichita, Kansas, 67214
Status
Address
Cancer Center of Kansas, PA - Winfield
Winfield, Kansas, 67156
Status
Address
Drs. Carrol, Sheth, Raghavan
Louisville, Kentucky, 40215
Status
Address
Hickman Cancer Center at Bixby Medical Center
Adrian, Michigan, 49221
Status
Address
Saint Joseph Mercy Cancer Center
Ann Arbor, Michigan, 48106-0995
Status
Address
CCOP - Michigan Cancer Research Consortium
Ann Arbor, Michigan, 48106
Status
Address
Oakwood Cancer Center at Oakwood Hospital and Medical Center
Dearborn, Michigan, 48123-2500
Status
Address
Green Bay Oncology, Limited - Escanaba
Escanaba, Michigan, 49431
Status
Address
Genesys Hurley Cancer Institute
Flint, Michigan, 48503
Status
Address
Hurley Medical Center
Flint, Michigan, 48503
Status
Address
Van Elslander Cancer Center at St. John Hospital and Medical Center
Grosse Pointe Woods, Michigan, 48236
Status
Address
Dickinson County Healthcare System
Iron Mountain, Michigan, 49801
Status
Address
Foote Memorial Hospital
Jackson, Michigan, 49201
Status
Address
Haematology-Oncology Associates of Ohio and Michigan, PC
Lambertville, Michigan, 48144
Status
Address
Sparrow Regional Cancer Center
Lansing, Michigan, 48912-1811
Status
Address
St. Mary Mercy Hospital
Livonia, Michigan, 48154
Status
Address
Community Cancer Center of Monroe
Monroe, Michigan, 48162
Status
Address
Mercy Memorial Hospital - Monroe
Monroe, Michigan, 48162
Status
Address
St. Joseph Mercy Oakland
Pontiac, Michigan, 48341-2985
Status
Address
Mercy Regional Cancer Center at Mercy Hospital
Port Huron, Michigan, 48060
Status
Address
Seton Cancer Institute at Saint Mary's - Saginaw
Saginaw, Michigan, 48601
Status
Address
St. John Macomb Hospital
Warren, Michigan, 48093
Status
Address
Alexandria, Minnesota, 56308
Status
Address
MeritCare Bemidji
Bemidji, Minnesota, 56601
Status
Address
Fairview Ridges Hospital
Burnsville, Minnesota, 55337
Status
Address
Mercy and Unity Cancer Center at Mercy Hospital
Coon Rapids, Minnesota, 55433
Status
Address
Duluth Clinic Cancer Center - Duluth
Duluth, Minnesota, 55805-1983
Status
Address
CCOP - Duluth
Duluth, Minnesota, 55805
Status
Address
Miller - Dwan Medical Center
Duluth, Minnesota, 55805
Status
Address
Fairview Southdale Hospital
Edina, Minnesota, 55435
Status
Address
Fergus Falls Medical Group, PA
Fergus Falls, Minnesota, 56537
Status
Address
Mercy and Unity Cancer Center at Unity Hospital
Fridley, Minnesota, 55432
Status
Address
Hutchinson Area Health Care
Hutchinson, Minnesota, 55350
Status
Address
HealthEast Cancer Care at St. John's Hospital
Maplewood, Minnesota, 55109
Status
Address
Minnesota Oncology Hematology, PA - Maplewood
Maplewood, Minnesota, 55109
Status
Address
Virginia Piper Cancer Institute at Abbott - Northwestern Hospital
Minneapolis, Minnesota, 55407
Status
Address
Hennepin County Medical Center - Minneapolis
Minneapolis, Minnesota, 55415
Status
Address
Hubert H. Humphrey Cancer Center at North Memorial Outpatient Center
Robbinsdale, Minnesota, 55422-2900
Status
Address
Mayo Clinic Cancer Center
Rochester, Minnesota, 55905
Status
Address
CentraCare Clinic - River Campus
Saint Cloud, Minnesota, 56303
Status
Address
Coborn Cancer Center
Saint Cloud, Minnesota, 56303
Status
Address
CCOP - Metro-Minnesota
Saint Louis Park, Minnesota, 55416
Status
Address
Park Nicollet Cancer Center
Saint Louis Park, Minnesota, 55416
Status
Address
Regions Hospital Cancer Care Center
Saint Paul, Minnesota, 55101
Status
Address
United Hospital
Saint Paul, Minnesota, 55102
Status
Address
St. Francis Cancer Center at St. Francis Medical Center
Shakopee, Minnesota, 55379
Status
Address
Ridgeview Medical Center
Waconia, Minnesota, 55387
Status
Address
Minnesota Oncology Hematology, PA - Woodbury
Woodbury, Minnesota, 55125
Status
Address
CCOP - Cancer Research for the Ozarks
Springfield, Missouri, 65802
Status
Address
St. John's Regional Health Center
Springfield, Missouri, 65804
Status
Address
Hulston Cancer Center at Cox Medical Center South
Springfield, Missouri, 65807
Status
Address
CCOP - Montana Cancer Consortium
Billings, Montana, 59101
Status
Address
Hematology-Oncology Centers of the Northern Rockies - Billings
Billings, Montana, 59101
Status
Address
Northern Rockies Radiation Oncology Center
Billings, Montana, 59101
Status
Address
St. Vincent Healthcare Cancer Care Services
Billings, Montana, 59101
Status
Address
Billings Clinic - Downtown
Billings, Montana, 59107-7000
Status
Address
Bozeman Deaconess Cancer Center
Bozeman, Montana, 59715
Status
Address
St. James Healthcare Cancer Care
Butte, Montana, 59701
Status
Address
Great Falls Clinic - Main Facility
Great Falls, Montana, 59405
Status
Address
Great Falls, Montana, 59405
Status
Address
Northern Montana Hospital
Havre, Montana, 59501
Status
Address
St. Peter's Hospital
Helena, Montana, 59601
Status
Address
Glacier Oncology, PLLC
Kalispell, Montana, 59901
Status
Address
Kalispell Medical Oncology at KRMC
Kalispell, Montana, 59901
Status
Address
Kalispell Regional Medical Center
Kalispell, Montana, 59901
Status
Address
Community Medical Center
Missoula, Montana, 59801
Status
Address
Guardian Oncology and Center for Wellness
Missoula, Montana, 59804
Status
Address
Montana Cancer Specialists at Montana Cancer Center
Missoula, Montana, 59807-7877
Status
Address
Montana Cancer Center at St. Patrick Hospital and Health Sciences Center
Missoula, Montana, 59807
Status
Address
Cancer Resource Center - Lincoln
Lincoln, Nebraska, 68510
Status
Address
CCOP - Missouri Valley Cancer Consortium
Omaha, Nebraska, 68106
Status
Address
Immanuel Medical Center
Omaha, Nebraska, 68122
Status
Address
Alegant Health Cancer Center at Bergan Mercy Medical Center
Omaha, Nebraska, 68124
Status
Address
Creighton University Medical Center
Omaha, Nebraska, 68131-2197
Status
Address
Rutherford Hospital
Rutherfordton, North Carolina, 28139
Status
Address
Bismarck Cancer Center
Bismarck, North Dakota, 58501
Status
Address
Medcenter One Hospital Cancer Care Center
Bismarck, North Dakota, 58501
Status
Address
Mid Dakota Clinic, PC
Bismarck, North Dakota, 58501
Status
Address
St. Alexius Medical Center Cancer Center
Bismarck, North Dakota, 58502
Status
Address
CCOP - MeritCare Hospital
Fargo, North Dakota, 58122
Status
Address
MeritCare Broadway
Fargo, North Dakota, 58122
Status
Address
Mary Rutan Hospital
Bellefontaine, Ohio, 43311
Status
Address
Wood County Oncology Center
Bowling Green, Ohio, 43402
Status
Address
Adena Regional Medical Center
Chillicothe, Ohio, 45601
Status
Address
Charles M. Barrett Cancer Center at University Hospital
Cincinnati, Ohio, 45267
Status
Address
North Coast Cancer Care - Clyde
Clyde, Ohio, 43410
Status
Address
Riverside Methodist Hospital Cancer Care
Columbus, Ohio, 43214-3998
Status
Address
CCOP - Columbus
Columbus, Ohio, 43215
Status
Address
Grant Medical Center Cancer Care
Columbus, Ohio, 43215
Status
Address
Mount Carmel Health - West Hospital
Columbus, Ohio, 43222
Status
Address
Doctors Hospital at Ohio Health
Columbus, Ohio, 43228
Status
Address
Grandview Hospital
Dayton, Ohio, 45405
Status
Address
Good Samaritan Hospital
Dayton, Ohio, 45406
Status
Address
David L. Rike Cancer Center at Miami Valley Hospital
Dayton, Ohio, 45409
Status
Address
Samaritan North Cancer Care Center
Dayton, Ohio, 45415
Status
Address
CCOP - Dayton
Dayton, Ohio, 45420
Status
Address
Grady Memorial Hospital
Delaware, Ohio, 43015
Status
Address
Hematology Oncology Center
Elyria, Ohio, 44035
Status
Address
Blanchard Valley Medical Associates
Findlay, Ohio, 45840
Status
Address
Middletown Regional Hospital
Franklin, Ohio, 45005-1066
Status
Address
Wayne Hospital
Greenville, Ohio, 45331
Status
Address
Charles F. Kettering Memorial Hospital
Kettering, Ohio, 45429
Status
Address
Fairfield Medical Center
Lancaster, Ohio, 43130
Status
Address
Lima Memorial Hospital
Lima, Ohio, 45804
Status
Address
Strecker Cancer Center at Marietta Memorial Hospital
Marietta, Ohio, 45750
Status
Address
Northwest Ohio Oncology Center
Maumee, Ohio, 43537-1839
Status
Address
St. Luke's Hospital
Maumee, Ohio, 43537
Status
Address
Licking Memorial Cancer Care Program at Licking Memorial Hospital
Newark, Ohio, 43055
Status
Address
Fisher-Titus Medical Center
Norwalk, Ohio, 44857
Status
Address
St. Charles Mercy Hospital
Oregon, Ohio, 43616
Status
Address
Toledo Clinic - Oregon
Oregon, Ohio, 43616
Status
Address
North Coast Cancer Care, Incorporated
Sandusky, Ohio, 44870
Status
Address
Mercy Medical Center
Springfield, Ohio, 45504
Status
Address
Community Hospital of Springfield and Clark County
Springfield, Ohio, 45505
Status
Address
Flower Hospital Cancer Center
Sylvania, Ohio, 43560
Status
Address
Mercy Hospital of Tiffin
Tiffin, Ohio, 44883
Status
Address
Toledo Hospital
Toledo, Ohio, 43606
Status
Address
St. Vincent Mercy Medical Center
Toledo, Ohio, 43608
Status
Address
Medical University of Ohio Cancer Center
Toledo, Ohio, 43614
Status
Address
CCOP - Toledo Community Hospital
Toledo, Ohio, 43617
Status
Address
St. Anne Mercy Hospital
Toledo, Ohio, 43623
Status
Address
Toledo Clinic, Incorporated - Main Clinic
Toledo, Ohio, 43623
Status
Address
UVMC Cancer Care Center at Upper Valley Medical Center
Troy, Ohio, 45373-1300
Status
Address
Fulton County Health Center
Wauseon, Ohio, 43567
Status
Address
Precision Radiotherapy at University Pointe
West Chester, Ohio, 45069
Status
Address
Mount Carmel St. Ann's Cancer Center
Westerville, Ohio, 43081
Status
Address
Clinton Memorial Hospital
Wilmington, Ohio, 45177
Status
Address
Ruth G. McMillan Cancer Center at Greene Memorial Hospital
Xenia, Ohio, 45385
Status
Address
Genesis - Good Samaritan Hospital
Zanesville, Ohio, 43701
Status
Address
Providence Milwaukie Hospital
Milwaukie, Oregon, 97222
Status
Address
Legacy Good Samaritan Hospital & Comprehensive Cancer Center
Portland, Oregon, 97210
Status
Address
Providence Cancer Center at Providence Portland Medical Center
Portland, Oregon, 97213-2967
Status
Address
Adventist Medical Center
Portland, Oregon, 97216
Status
Address
CCOP - Columbia River Oncology Program
Portland, Oregon, 97225
Status
Address
Providence St. Vincent Medical Center
Portland, Oregon, 97225
Status
Address
Northwest Cancer Specialists at Rose Quarter Cancer Center
Portland, Oregon, 97227
Status
Address
Knight Cancer Institute at Oregon Health and Science University
Portland, Oregon, 97239-3098
Status
Address
Geisinger Cancer Institute at Geisinger Health
Danville, Pennsylvania, 17822-0001
Status
Address
Geisinger Hazleton Cancer Center
Hazleton, Pennsylvania, 18201
Status
Address
Geisinger Medical Group - Scenery Park
State College, Pennsylvania, 16801
Status
Address
Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center
Wilkes-Barre, Pennsylvania, 18711
Status
Address
AnMed Cancer Center
Anderson, South Carolina, 29621
Status
Address
CCOP - Upstate Carolina
Spartanburg, South Carolina, 29303
Status
Address
Gibbs Regional Cancer Center at Spartanburg Regional Medical Center
Spartanburg, South Carolina, 29303
Status
Address
Rapid City Regional Hospital
Rapid City, South Dakota, 57701
Status
Address
Medical X-Ray Center, PC
Sioux Falls, South Dakota, 57105
Status
Address
Sanford Cancer Center at Sanford USD Medical Center
Sioux Falls, South Dakota, 57117-5039
Status
Address
Fredericksburg Oncology, Incorporated
Fredericksburg, Virginia, 22401
Status
Address
Southwest Washington Medical Center Cancer Center
Vancouver, Washington, 98668
Status
Address
Luther Midlelfort Hospital
Eau Claire, Wisconsin, 54702
Status
Address
Midelfort Clinic - Luther
Eau Claire, Wisconsin, 54703-1510
Status
Address
Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
Green Bay, Wisconsin, 54301-3526
Status
Address
Green Bay Oncology, Limited at St. Mary's Hospital
Green Bay, Wisconsin, 54303
Status
Address
St. Mary's Hospital Medical Center - Green Bay
Green Bay, Wisconsin, 54303
Status
Address
St. Vincent Hospital Regional Cancer Center
Green Bay, Wisconsin, 54307-3508
Status
Address
Holy Family Memorial Medical Center Cancer Care Center
Manitowoc, Wisconsin, 54221-1450
Status
Address
Bay Area Cancer Care Center at Bay Area Medical Center
Marinette, Wisconsin, 54143
Status
Address
Green Bay Oncology, Limited - Oconto Falls
Oconto Falls, Wisconsin, 54154
Status
Address
Green Bay Oncology, Limited - Sturgeon Bay
Sturgeon Bay, Wisconsin, 54235
Status
Address
Rocky Mountain Oncology
Casper, Wyoming, 82609
Status
Address
Welch Cancer Center at Sheridan Memorial Hospital
Sheridan, Wyoming, 82801
